Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated announced the granting of inducement awards to 24 new employees as part of its hiring strategy, compliant with NASDAQ Listing Rule 5635(c)(4). The inducement grants include options to purchase a total of 182,880 shares of common stock at an exercise price reflecting the latest trading price. Options have a 10-year term with a progressive vesting schedule, aimed at retaining talent within the company. Insmed continues to focus on developing therapies for serious diseases, reinforcing its commitment to innovation and patient care.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inducement awards granted to 24 new employees, fostering growth.
  • Stock options provided at a competitive exercise price.
  • Company is advancing a promising pipeline targeting unmet needs.

Full Press Release Details

BRIDGEWATER, N.J. , April 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on April 3, 2023 to purchase an aggregate 182,880 shares of Insmed common stock at an exercise price of $17.37 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What is the purpose of inducement awards at Insmed?

Inducement awards are granted to new employees as a material incentive for joining Insmed.

How many new employees received stock options at Insmed?

A total of 24 new employees received stock options at Insmed.

What is the exercise price for Insmed's stock options?

The exercise price for the stock options is $17.37 per share.

What is the vesting schedule for stock options at Insmed?

The options vest over four years, with 25% vesting after one year.

What areas does Insmed focus on in its research?

Insmed targets serious unmet needs in inflammatory diseases and rare pulmonary disorders.

Last updated: Apr 6, 2023